Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher A Chanan Khan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Jun 19 2017

Fingerprint

Multiple Myeloma
Delivery of Health Care
Geographic Locations
Insurance Carriers
Vulnerable Populations
Social Class
Patient Care
Therapeutics
Research

Keywords

  • Disparity
  • Myeloma
  • Outcomes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Equal Treatment and Outcomes for Everyone with Multiple Myeloma : Are We There Yet? / Ailawadhi, Sikander; Bhatia, Kirtipal; Aulakh, Sonikpreet; Meghji, Zahara; Chanan Khan, Asher A.

In: Current Hematologic Malignancy Reports, 19.06.2017, p. 1-8.

Research output: Contribution to journalArticle

@article{0b00e3726c95489eaa2dc19c463c1365,
title = "Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?",
abstract = "Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.",
keywords = "Disparity, Myeloma, Outcomes",
author = "Sikander Ailawadhi and Kirtipal Bhatia and Sonikpreet Aulakh and Zahara Meghji and {Chanan Khan}, {Asher A}",
year = "2017",
month = "6",
day = "19",
doi = "10.1007/s11899-017-0393-y",
language = "English (US)",
pages = "1--8",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Equal Treatment and Outcomes for Everyone with Multiple Myeloma

T2 - Are We There Yet?

AU - Ailawadhi, Sikander

AU - Bhatia, Kirtipal

AU - Aulakh, Sonikpreet

AU - Meghji, Zahara

AU - Chanan Khan, Asher A

PY - 2017/6/19

Y1 - 2017/6/19

N2 - Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.

AB - Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.

KW - Disparity

KW - Myeloma

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85020529106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020529106&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0393-y

DO - 10.1007/s11899-017-0393-y

M3 - Article

C2 - 28626849

AN - SCOPUS:85020529106

SP - 1

EP - 8

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -